Coumestrol, which is predominantly found in soybean products as a phytoestrogen, has cancer preventive activities in estrogen-responsive carcinomas. However, effects and molecular targets of coumestrol have not been reported for epithelial ovarian cancer (EOC). In the present study, we demonstrated that coumestrol inhibited viability and invasion and induced apoptosis of ES2 (clear cell-/serous carcinoma origin) cells. In addition, immunoreactive PCNA and ERBB2, markers of proliferation of ovarian carcinoma, were attenuated in their expression in coumestrol-induced death of ES2 cells. Phosphorylation of AKT, p70S6K, ERK1/2, JNK1/2, and p90RSK was inactivated by coumestrol treatment in a dose-and timedependent manner as determined in western blot analyses. Moreover, PI3K inhibitors enhanced effects of coumestrol to decrease phosphorylation of AKT, p70S6K, S6, and ERK1/2. Furthermore, coumestrol has strong cancer preventive effects as compared to other conventional chemotherapeutics on proliferation of ES2 cells. In conclusion, coumestrol exerts chemotherapeutic effects via PI3K and ERK1/2 MAPK pathways and is a potentially novel treatment regimen with enhanced chemoprevention activities against progression of EOC.
Introduction
Phytoestrogens are natural polyphenolic compounds found mostly in soybeans, legumes, oilseeds, and nuts. Most of them have anti-estrogenic properties that may make them effective therapeutic agents. The molecular events activated by estrogen involve direct binding of estrogens to estrogen receptor alpha (ESR1) or beta (ESR2) to regulate transcription of genes after recruitment of other transcription factors such as AP1 and TF leading to proliferation, migration and invasion of cells (Heldring et al. 2007) . Therefore, blocking the activity of ESR1/ESR2 in the signal transduction pathway is important for reversing development of estrogen-responsive diseases such as cancer. Structural similarities between 17b-estradiol (E 2 ) and phytoestrogens involve binding cytoplasmic/ nuclear ESR1/ESR2 or membrane receptors for estrogen receptors (GPER), which may prevent osteoporosis, cardioeffects on various cancer cells (Virk-Baker et al. 2010) . Phytoestrogens are classified into four main subunits including isoflavones (genistein and diadzein), lignans (enterolactone and enterodiol), coumestans (coumestrol), and stilbenes (resveratrol).
Coumestrol is a major representative of a phytoestrogen naturally found in soybeans, legumes, brussel sprouts, and spinach. It has potential therapeutic activities against carcinogenesis, neurological disorders, and autoimmune diseases through action as an antagonist to estrogen or other estrogenic chemicals for binding to ESR1/ESR2 (Schoenroth et al. 2004 , Musgrove & Sutherland 2009 , de Leeuw et al. 2011 . Coumestrol acts as a novel inhibitor of protein kinase CK2 which is a abundantly expressed in human cancers including epithelial ovarian cancer (EOC) and is closely linked to cell proliferation, inhibition of apoptosis and oncogenesis in various cancer cell lines from the cervix, lung and prostate, as well as leukemic cells (Ahmad et al. 2008 , Duncan & Litchfield 2008 , Liu et al. 2013 , Cho et al. 2014 . In addition, coumestrol induces cellular senescence by stimulating production of ROS through p53-p21
Cip1/WAF1 signal transduction cascades in breast and colon cancer cells (Lee et al. 2013) . In addition, coumestrol induces expression of related genes in the endoplasmic reticulum associated with stress and inflammatory stress responses and intrinsic and extrinsic apoptosis in MCF7:5C breast cancer cells (Obiorah et al. 2014) . Moreover, in hypoxic PC3 prostate cancer cells, coumestrol inhibits HIF1a that is required for tumorigenesis and metastasis of solid tumors under hypoxic conditions (Cho et al. 2014) . Whereas, the most well-characterized mode of phytoestrogen action is through ESR1/ESR2 binding which induces long-term genomic effects by mediating gene transcription, phytoestrogens can also modulate a wide array of intracellular signaling cascades through binding to cell surface GPER and/or various growth factor receptors. They are known to inhibit the activity of protein tyrosine kinases which regulate transcription of estrogen receptors or recruitment of other co-transcriptional factors such as AP-1 and NFkB, leading to suppression of tumorigenesis (Heldring et al. 2007) . For example genistein, one of the phytoestrogens, affects transcriptional activity of ESR1 and ESR2 by modulating their binding affinity to estrogen-response elements (ERE) and inhibiting activity of both the PI3K/AKT and MAPK cell signaling pathways (Shimizu & Weinstein 2005 , Anastasius et al. 2009 , Barnes 2010 . The PI3K/AKT and MAPK signaling pathways are closely implicated in survival, growth, and proliferation of cancer cells, and their over-expression/activation have been identified in ovarian cancer patients, suggesting that these pathways are involved in ovarian cancer promotion (Yuan et al. 2000 , Altomare et al. 2004 , Kuo et al. 2009 , Cotrim et al. 2013 , Bilal et al. 2014 . Thus, down-regulation/or inactivation of these pathways by phytoestrogens could inhibit ovarian carcinogenesis. Nevertheless, the molecular mechanisms of anti-cancer activity and chemoresistance induced by coumestrol in EOC are poorly understood. Ovarian cancer is the most fatal malignancy of the female reproductive tract and is the fifth leading cause of cancer deaths in women in the United States in 2015 (Siegel et al. 2015) . EOC that originates from the ovarian surface epithelia is a common type of ovarian cancer accounting for about 90% of the cases and has a low 5-year survival rate (27%) due to lack of methods for early diagnosis and early detection of symptoms (Jayson et al. 2014) . EOC can be classified into four histological subtypes: serous carcinoma (SC), endometrioid carcinoma, mucinous carcinoma and clear cell carcinoma (CCC) (Kaku et al. 2003) . The main treatment for EOC is cytoreductive surgery followed by platinum-or taxane-based chemotherapy. However, highgrade SC or ovarian CCC are relatively resistance to standard chemotherapy which is a combination of drugs including cisplatin (a platinum-based drug) and paclitaxel (a taxane-based drug) and poor prognosis (Tan & Kaye 2007 , Itamochi et al. 2008 , Vaughan et al. 2011 . Despite various difficulties in successfully treating ovarian EOC, therapeutic mechanisms for successful treatment of chemotherapy-resistant subtypes in women are clearly needed. Hence, it is necessary to identify the mechanisms responsible for resistance to cancer preventive therapies and develop new therapeutic approaches to overcome chemoresistance which prevents apoptosis through defects in signal transduction mechanisms in ovarian CCC/SC.
In the current study, we investigated the biological activity of coumestrol on various signal transduction cascades in ES2 cells. The purpose of this study was to determine: i) inhibitory effects of coumestrol on proliferation and invasion of immortalized ES2 cells; ii) the signaling mechanisms mediated by coumestrol through AKT and MAPKs pathways in ES2 cells; and iii) the cancer preventive activity of coumestrol compared with traditional cancer therapeutic regimens on ES2 cells. We hypothesized that coumestrol induces cell death in ES2 cells by suppressing PI3K/AKT and MAPK signal transduction cascades. Our findings support our hypothesis and suggest that coumestrol inhibits progression and development of EOC and that combination chemotherapy including coumestrol may increase survival rates of women with EOC.
Materials and methods

Chemicals
Coumestrol, cisplatin and paclitaxel were purchased from Sigma-Aldrich, Inc. Rapamycin (mTOR inhibitor), SB203580 (P38 inhibitor), and U0126 (ERK1/2 inhibitor) were from Enzo Life Science (Farmingdale, NY, USA) and LY294002 (PI3K/AKT inhibitor) was from Cell Signaling Technology (Beverly, MA, USA w70% of the insert membrane growth area, using a DM3000 (Leica) microscope. The entire experiment was repeated at least three times.
TUNEL assay
The ES2 cells (3!10 4 cells per 300 ml) were seeded on confocal dishes (Cat No.: 100350, SPL Life Science, Seoul, Republic of Korea) and then incubated for 24 h in serumfree McCoy's 5A medium. Cells were then treated with coumestrol at a final concentration of 50 mM for 48 h at 37 8C in a CO 2 incubator. After incubation, the cells were air dried and fixed with 4% paraformaldehyde in PBS for 1 h at room temperature. The cells were rinsed with PBS briefly and permeabilized using 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. Then, the cells were subjected to TUNEL staining mixture using the In Situ Cell Death Detection kit, TMR red (Roche) for 1 h at 37 8C in the dark. Cells were then washed with PBS and overlaid with DAPI (Cat No.: D8417, Sigma). Fluorescence was detected using a LSM710 (Carl Zeiss, Oberkochen, Germany) confocal microscope fitted with a digital microscope AxioCam camera with Zen2009 software. Visualization of TUNEL-positive cells allowed assessment of changes in apoptotic cell numbers and total numbers of cells in culture using DAPI to stain nuclei. TUNEL-positive cells were identified using confocal imaging.
Immunofluorescence microscopy
The effects of coumestrol on the expression of PCNA and ERBB2 were determined by immunofluorescence microscopy. The ES2 cells ( 
Western blot analysis
Whole-cell lysates were obtained from cells following treatment with RIPA buffer containing protease inhibitor cocktails (Roche). Concentrations of protein in whole-cell extracts were determined using the Bradford protein assay (Bio-Rad) with BSA as the standard. Twenty micrograms denatured proteins were loaded, separated using SDS-PAGE and then transferred to nitrocellulose. Blots were developed using enhanced chemiluminescence detection (SuperSignal West Pico, Pierce, Rockford, IL, USA) and quantified by measuring the intensity of light emitted from correctly sized bands under ultraviolet light using a ChemiDoc EQ system and Quantity One software (Bio-Rad). Immunoreactive proteins were detected using goat anti-rabbit polyclonal antibodies against phospho-proteins and total-proteins at a 1:1000 dilution and 10% SDS/PAGE gel. As a loading control, total proteins were used to normalize results from detection of proteins by western blotting. All antibodies were from Cell Signaling Technology. Multiple exposures of each western blot were performed to ensure linearity of chemiluminescent signals.
Signal intensities of phosphorylated (p)-proteins in blot images were normalized based on the signal intensity from total protein. For analyses of dose-dependent and time-dependent effects, fold-changes in the normalized abundance of p-proteins were determined in comparison to control cells (first lane in all blots). Data from at least three independent experiments were used to calculate meansGS.E.M.
Statistical analysis
Data from western blot analyses, proliferation and invasion assays were subjected to ANOVA according to the general linear model (PROC-GLM) of the SAS program (SAS Institute, Cary, NC, USA) to determine whether there were significant effects on abundance of p-proteins, proliferation or invasion of ES2 cells in response to treatments. Differences with a probability value of P!0.05 were considered statistically significant. Data are presented as meanGS.E.M. unless otherwise stated.
Results
Coumestrol suppresses cellular activities of ES2 cells
To determine the action of coumestrol on ES2 cells from human ovary, we measured cell proliferation of ES2 cells treated with coumestrol in a dose-dependent manner (0, 1, 10, 20, 50, and 100 mM) as illustrated in Fig. 1A . Coumestrol suppressed proliferation of ES2 cells in a dose-dependent manner with IC 50 being 50 mM (P!0.01). Using this concentration of coumestrol, we investigated the effect of coumestrol on invasiveness of ES2 cells by Transwell invasion analyses ( Fig. 1B and C) . Coumestrol treatment of ES2 cells decreased invasiveness by w57% (P!0.001) compared to non-treated ES2 cells. As shown in Fig. 1D , coumestrol induced DNA fragmentation leading to apoptosis of ES2 cells as evidenced by red fluorescence in the nucleus. On the other hand, apoptotic cells were not detected in the untreated ES2 control cells. These results reveal that the coumestrol possesses anticarcinogenic effects on ES2 cells, such as attenuating proliferation and migration of ES2 cells.
Coumestrol inhibits expression of PCNA and ERBB2 in ES2 cells
Next, we determined the expression of representative markers of proliferation of ovarian cancer such as PCNA and ERBB2 between coumestrol-treated and untreated ES2 cells by immunofluorescence analyses (Fig. 2) . PCNA was mainly localized in the nucleus in ES2 cells, but its expression was detected only faintly in nuclei of coumestrol-treated ES2 cells. Expression of ERBB2 in ES2 cells was also decreased by coumestrol compared with non-treated ES2 cells which had abundant expression in the plasma membrane. These results indicate that coumestrol reduces proliferative activity of ES2 cells. 
Coumestrol reduces phosphorylation of PI3K/AKT and MAPK in ES2 cells
To investigate the effect of coumestrol on the PI3K/AKT and MAPK signaling pathways in ES2 cells, we performed western blot analyses in a dose-(0, 10, 20 and 50 mM) and time-(0, 5, 15, 30, 60, and 120 min) dependent manner.
As illustrated in Fig. 3 , coumestrol decreased the abundance of phosphorylated AKT, -p70S6K, -ERK1/2, -JNK1/2 and -p90RSK in ES2 cells in a dose-dependent manner. However, the phosphorylation of p38 increased in response to coumesterol treatment of ES2 cells. The results were that phosphorylated AKT increased at 5 min after coumestrol treatment and then decreased significantly after 15 min of coumestrol treatment (Fig. 4A) . Phosphorylation of p70S6K increased at 15 min of coumestrol treatment of ES2 cells, but then decreased significantly after 30 min of incubation of ES2 cells with coumestrol ( Fig. 4B) . To identify the signaling mechanism mediated by coumestrol in ES2 cells, we confirmed the phosphorylation of S6, which is downstream of p70S6K in ES2 cells incubated coumestrol (Fig. 4C) . Phosphorylation of S6 was abundant in non-treated ES2 cells, but phosphorylated-S6 was decreased in a time-dependent manner in response to treatment of ES2 cells with coumesterol. In addition, phosphorylated ERK1/2 and JNK1/2 decreased significantly after 15 min and 5 min of coumestrol incubation respectively compared with basal levels ( Fig. 4D and E) . Similarly, the abundance of phosphorylated-p90RSK decreased in a time-dependent manner in ES2 cells treated with coumestrol (Fig. 4F) . These results indicate that coumestrol suppresses activity of protein kinases related in PI3K and MAPK signaling mechanism in a dose-and time-dependent manner.
PI3K/AKT and MAPK signaling decreases phosphorylation of AKT, p70RSK, S6, and ERK1/2 in ES2 cells treated with coumestrol
To identify cell signaling pathways mediated by coumestrol, ES2 cells were pretreated with specific inhibitors of PI3K (LY294002, 20 mM), p38 MAPK (SB203580, 20 mM) and ERK1/2 MAPK (U0126, 10 mM) pathways individually or in combination prior to treatment with coumestrol. Treatment of ES2 cells with LY294002, SB203580, or U0126 along with coumestrol had greater effects of coumestrol to inhibit phosphorylation of AKT compared with coumestrol treatment only, but the effects were not statistically significant (PO0.05) (Fig. 5A) . The reduced abundance of p-AKT proteins in coumestrol treated cells declined further (P!0.05) in cells treated with coumestrol plus all three inhibitors, as compared with that for treatment of cells with coumestrol alone-or coumestrol plus LY294002. Treatment of ES2 cells with LY294002 or U0126 along with coumestrol reduced tendencies for (E), and p90RSK (F) was determined in ES2 cells treated with coumestrol using western blot analyses. Blots were imaged to estimate relative changes in abundance of phosphorylated protein relative to total protein.
The asterisks denote statistically significant effects of treatment (*P!0.05, **P!0.01 and ***P!0.001).
coumestrol to decrease p-p70S6K and p-S6 abundance compared with coumestrol treatment only, but the effect was not statistically significant (PO0.05) ( Fig. 5B and C) . The reduced abundance of p-S6 proteins in coumestrol treated cells declined further (P!0.05) when cells were treated with coumestrol plus inhibitor combinations (LY294002 plus SB203580, LY294002 plus U0126, all three inhibitors), compared with that for cells treated with coumestrol alone. However, SB203580 or U0126 plus coumestrol did not influence the abundance of phosphorylated p70S6K or -S6 as compared with coumestrol treatment alone. Furthermore, reduced abundance of p-ERK1/2 in the presence of coumestrol decreased more in ES2 cells in response to additional treatments with LY294002, U0126 or the combination of inhibitors with coumestrol, whereas additional treatment with SB203580 did not affect the abundance of p-ERK1/2 (Fig. 5D ). These results show that inhibition of p70RSK and S6 activation by coumestrol on ES2 cells could be partly through inactivation of PI3K/AKT and ERK1/2 MAPK which ultimately suppresses protein synthesis and proliferation of ES2 cells.
PI3K/AKT/mTOR and MAPK inhibitors inhibit proliferative activity of ES2 cells treated with coumestrol
To support the association between coumestrol-mediated PI3K/AKT/mTOR, ERK1/2 MAPK and p38 MAPK cell signaling and the influence of coumestrol on ES2 cell proliferation, we conducted cell proliferation assays in the presence or absence of coumestrol, LY294002, SB203580, U0126, and rapamycin (mTOR inhibitor, 10 mM) (Fig. 6) . Consistent with previous results, coumestrol reduced the proliferation of ES2 cells by about 50% (P!0.01). Treatment of SB203580 rapamycin (P!0.01) or U0126 (P!0.05) before incubation of ES2 cells with coumestrol slightly increased the ES2 cell proliferation compared to coumestrol treatment alone. On the other hand, SB203580 or rapamycin alone increased proliferation of ES2 cells compared with non-treated cells, and the effects of SB203580 and rapamycin were inhibited when cells were also co-treated with coumestrol. In comparison with non-treated cells, treatment of ES2 cells with LY294002 alone did not have a significant effect on cell proliferation, while co-treatment of coumestrol and LY294002 decreased cell proliferation. There were no differential changes in proliferation of ES2 cells between U0126 plus or minus coumestrol. These results indicate that coumestrol has greater anti-proliferative effects on ES2 cells than blockage of PI3K and MAPK signal transduction cascades.
Coumestrol possesses cancer preventive effects on ES2 cells as compared with cisplatin and paclitaxel
To estimate cytotoxicity of coumestrol against ES2 cells, we investigated viability of ES2 cells treated with coumestrol, paclitaxel (a taxane-based agent) or cisplatin (a platinum-based agent) and the combination of these chemicals. As illustrated in Fig. 7 , a monotherapy with coumestrol (50 mM), paclitaxel (20 mM) or cisplatin (50 mM) inhibited (P!0.05) proliferation of ES2 cells by 54, 70, and 64% compared with non-treated ES2 control cells (100%). In comparison between monotherapy treatments, coumestrol alone had a greater effect to reduce cell proliferation than either paclitaxel-or cisplatin alone. In addition, the combined therapies using coumestrol plus paclitaxel, coumestrol plus cisplatin, and coumestrol plus paclitaxel plus cisplatin) suppressed (P!0.05) survival of ES2 cells compared with non-treated ES2 cells. Specifically, coumestrol increased sensitivity of ES2 cells to paclitaxel as evidenced by a 21% decrease (P!0.05) in cell proliferation compared with treatment with paclitaxel alone. These results suggest that monotherapy with coumestrol is as effective as conventional chemotherapies including paclitaxel or cisplatin and that coumestrol may be more effective than paclitaxel-based chemotherapy for treatment of EOC.
Discussion
Coumesterol is a phytoestrogen known to act as an antagonist to estrogen and other estrogenic chemicals for binding to ESRs/GPER (Musgrove & Sutherland 2009 , de Leeuw et al. 2011 . Based on epidemiological analyses, coumestrol from soybean products may reduce the incidence of EOC (Bandera et al. 2011) . However, the signal transduction mechanism whereby coumestrol   a   180  160  140  120  100  80  60  40  20  0  -----+ 
LY294002 ( functions to reduce EOC is not known. In the present study, we determined the effects of coumestrol on proliferation of ES2 cells. As illustrated in Fig. 1 , coumestrol suppressed viability and invasivness while increasing apoptosis of ES2 cells. To eliminate potential cytotoxic effects of coumesterol in invasion assays, the cells were treated with coumestrol for only 12 h which is less than the doubling time of ES2 cells and too short of an exposure time to significantly affect proliferation of ES2 cells. Although, these results support that inhibition of invasion/migration by coumestrol independent of cytotoxic effects, potential influences of coumesterol on cell proliferation cannot be ruled out completely. Moreover, coumestrol decreased expression of markers of cell proliferation, PCNA, and ERBB2, in ES2 cells. Expression of PCNA and ERBB2 is abundant in the advanced stages of ovarian carcinoma (Khalifa et al. 1994) . Specifically, increases in PCNA activate cell proliferation through cell cycle regulation which leads to poor survival rates for EOC patients. In addition, ERBB2 amplification is frequently detected in clear cell types of ovarian cancer (Fujimura et al. 2002) . Thus, inhibition of proliferation, invasion, expression of genes regulating cell proliferation and enhanced apoptosis were signature effects of coumesterol on ES2 cells. The results of this study suggest that the antiproliferative activity of coumestrol on ES2 cell is a consequence of increasing apoptotic signaling pathways through inactivation of phosphorylation of signaling molecules in the PI3K-AKT-mTOR and ERK1/2 and JNK1/2 MAPK pathways. In the development of EOC, blockage of expression of downstream protein kinases of the PI3K signal transduction pathway prolongs diseasefree interval and enhances overall survival in patients with ovarian CCC (Jin et al. 2014) . Moreover, the RAS-MEK-ERK pathway activated by EGFR is considered a potential therapeutic target for ovarian CCC (Bartholomeusz et al. 2012) . A tyrosine kinase inhibitor (erlotinib) that acts on the EGFR and a MEK inhibitor (selumetinib) suppress proliferation of CCC cells through reduction of phosphorylated ERK1/2 and induction of G 1 arrest. Furthermore, a dual inhibitor of PI3K/mTOR signaling can overcome drug resistance of ovarian CCC (Oishi et al. 2014) . In the present study, we assessed effects of pharmacological inhibitors including LY294002 (PI3K inhibitor), SB203580 (p38 MAPK inhibitor), and U0126 (ERK1/2 inhibitor) on coumestrol-reduced phosphorylation of signaling molecule in ES2 cells with respect to roles of PI3K and MAPK signaling pathways on coumestrol-induced apoptosis. Our results revealed that the combined treatment of coumestrol and LY294002 reduced the activity of phosphor-AKT, -p70S6K, -S6 and -ERK1/2 compared with a single treatment of ES2 cells with coumestrol. AKT signaling is frequently activated in cisplatin-resistant cells of ovarian CCC and phosphorylates p70S6K and S6 stimulating translation of proteins required for cell proliferation and migration (Schmelzle & Hall 2000 , Mabuchi et al. 2009 ). In addition, AKT and ERK1/2 often converge to phosphorylate the same protein kinases by promoting cross-talk (Mendoza et al. 2011) . On the other hand, a synergistic effect was not observed for ES2 cell proliferation when coumestrol was combined with LY294002, SB203580, U0126, or rapamycin (mTOR inhibitor) even though these pharmacological inhibitors enhanced chemopreventive effects of ovarian CCC. Taken together these results suggest that coumestrol may effectively reverse development of CCC in human ovaries. The resistance of ovarian CCC to platinum-based regimens is considered a principle clinical problem in the management of that disease. To improve the response and survival rates of CCC patients, combination chemotherapy using paclitaxel with a platinum-based agent is commonly used as a standard first-line therapy after surgical cytoreduction (Thigpen et al. 1994) . In the present study, we compared the therapeutic activity of coumestrol with traditional chemotherapeutic agents including paclitaxel and cisplatin. Results of this study indicated that the chemopreventive efficacy of coumestrol on proliferation of ES2 cells was greater than that of either cisplatin or paclitaxel. Moreover, the combination of the anti-cancer therapeutics with coumestrol decreased viability of ES2 cells compared to the conventional single agent treatment. These results suggest that coumestrol may be a natural chemopreventive agent against the proliferation of chemotherapy resistant-ovarian cancer cells. However, clinical trials are required for development of dietary supplements or other regimens for treatment of patients with ovarian cancer with coumestrol. Since the ES2 cell line was established in the late 1980s, the cell line has been widely used in studies of ovarian CCC. The significant molecular and biological features of ovarian CCC are mutations of ARID1A or PIK3CA, positive staining for HNF1b and similarities in gene expression profiles with endometrial cancer and renal CCC (del Carmen et al. 2012) . However, recent studies question the use of ES2 cells as representative of CCC and suggest that the cell line is more likely of SC origin, based on unusual features distinct from other ovarian CCC (Domcke et al. 2013) . Further investigation is needed to elucidate more precisely the subtype-specific roles and signaling mechanisms of coumestrol.
In conclusion, results of this study provide the first in vitro evidence of chemotherapeutic activity by coumestrol for treatment of human EOC. Coumestrol suppressed survival rates of ES2 cells via inhibition of proliferation and invasion and stimulated apoptosis. In addition, coumestrol blocked phosphorylation and activation of PI3K/AKT and RAS/MAPKs cell signaling pathways in ES2 cells as illustrated in Fig. 8 . Also, a combination of coumestrol and current anti-cancer drugs could lead to a more effective and less harmful treatment of ovarian CCC/SC. Therefore, these results suggest that coumestrol has great potential as a cancer preventive therapeutic for treatment of human EOC.
Declaration of interest
